Animal models of NASH: Getting both pathology and metabolic context right

Non‐alcoholic fatty liver disease (NAFLD) is the most common cause of referral to liver clinics, and its progressive form, non‐alcoholic steatohepatitis (NASH), can lead to cirrhosis and end‐stage liver disease. The main risk factors for NAFLD/NASH are the metabolic abnormalities commonly observed in metabolic syndrome: insulin resistance, visceral obesity, dyslipidemia and altered adipokine profile. At present, the causes of progression from NAFLD to NASH remain poorly defined, and research in this area has been limited by the availability of suitable animal models of this disease. In the past, the main models used to investigate the pathogenesis of steatohepatitis have either failed to reproduce the full spectrum of liver pathology that characterizes human NASH, or the liver pathology has developed in a metabolic context that is not representative of the human condition. In the last few years, a number of models have been described in which the full spectrum of liver pathology develops in an appropriate metabolic context. In general, the underlying cause of metabolic defects in these models is chronic caloric overconsumption, also known as overnutrition. Overnutrition has been achieved in a number of different ways, including forced feeding, administration of high‐fat diets, the use of genetically hyperphagic animals, or a combination of these approaches. The purpose of the present review is to critique the liver pathology and metabolic abnormalities present in currently available animal models of NASH, with particular focus on models described in approximately the last 5 years.

[1]  M. Yeh,et al.  MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. , 2008, Journal of hepatology.

[2]  G. Farrell,et al.  VAT fat is bad for the liver, SAT fat is not! , 2008, Journal of gastroenterology and hepatology.

[3]  R. Green,et al.  Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet , 2008 .

[4]  M. Yeh,et al.  Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. , 2008, Journal of hepatology.

[5]  M. Yeh,et al.  Activation of peroxisome proliferator‐activated receptor α by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation , 2008, Journal of gastroenterology and hepatology.

[6]  R. Jeffery,et al.  Evidence Implicating Eating as a Primary Driver for the Obesity Epidemic , 2007, Diabetes.

[7]  M. Honda,et al.  Lipid‐induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet , 2007, Hepatology.

[8]  M. Yeh,et al.  Pathology of nonalcoholic fatty liver disease. , 2007, American journal of clinical pathology.

[9]  A. McCullough The Epidemiology and Risk Factors of NASH , 2007 .

[10]  M. Nishida,et al.  Abdominal obesity exhibits distinct effect on inflammatory and anti-inflammatory proteins in apparently healthy Japanese men , 2007, Cardiovascular diabetology.

[11]  G. Michalopoulos,et al.  Lack of Fas antagonism by Met in human fatty liver disease , 2007, Nature Medicine.

[12]  C. Larter Not all models of fatty liver are created equal: Understanding mechanisms of steatosis development is important , 2007, Journal of gastroenterology and hepatology.

[13]  Jian-Gao Fan,et al.  Effects of nonalcoholic fatty liver disease on the development of metabolic disorders , 2007, Journal of gastroenterology and hepatology.

[14]  G. Farrell,et al.  Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health , 2007, Journal of gastroenterology and hepatology.

[15]  S. McCall,et al.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis , 2007, Hepatology.

[16]  Khean-Lee Goh,et al.  How common is non‐alcoholic fatty liver disease in the Asia–Pacific region and are there local differences? , 2007, Journal of gastroenterology and hepatology.

[17]  T. Ueno,et al.  Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. , 2007, Metabolism: clinical and experimental.

[18]  C. Romestaing,et al.  Long term highly saturated fat diet does not induce NASH in Wistar rats , 2007, Nutrition & metabolism.

[19]  H. Iwaasa,et al.  Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high‐fat diet , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[20]  S. Kahn,et al.  Review: The role of insulin resistance in nonalcoholic fatty liver disease. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  R. E. Pitas,et al.  Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1 s⃞ Published, JLR Papers in Press, July 8, 2006. , 2006, Journal of Lipid Research.

[22]  D. Kleiner,et al.  comparison Of Adult And Pediatric Nafld—confirmation Of A Second Pattern Of Progressive Fatty Liver Disease In Children : 189 , 2006 .

[23]  G. Svegliati-Baroni,et al.  A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. , 2006, The American journal of pathology.

[24]  H. Cortez‐Pinto,et al.  Non-alcoholic steatohepatitis and metabolic syndrome , 2006, Current opinion in clinical nutrition and metabolic care.

[25]  Y. Huang,et al.  High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. , 2006, Life sciences.

[26]  Diego G. Silva,et al.  Fat aussie--a new Alström syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis. , 2006, Molecular endocrinology.

[27]  G. Zoppini,et al.  Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease , 2006, Clinical endocrinology.

[28]  J. Kuroda,et al.  Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. , 2006, European journal of pharmacology.

[29]  N. Petrovsky,et al.  Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. , 2006, Biochemical and biophysical research communications.

[30]  N. Maeda,et al.  Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. , 2006, Journal of hepatology.

[31]  R. Goldin,et al.  Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research , 2006, International journal of experimental pathology.

[32]  G. Farrell,et al.  Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? , 2006, Journal of hepatology.

[33]  M. Czaja,et al.  Jnk1 but not jnk2 promotes the development of steatohepatitis in mice , 2006, Hepatology.

[34]  I. Leclercq,et al.  NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. , 2005, Gastroenterology.

[35]  G. Pacini,et al.  Hypoadiponectinemia Predicts the Severity of Hepatic Fibrosis and Pancreatic Beta-Cell Dysfunction in Nondiabetic Nonobese Patients with Nonalcoholic Steatohepatitis , 2005, The American Journal of Gastroenterology.

[36]  D. Koop,et al.  Steatohepatitis induced by intragastric overfeeding in mice , 2005, Hepatology.

[37]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[38]  M. Czaja,et al.  Hepatocyte CYP2E1 Overexpression and Steatohepatitis Lead to Impaired Hepatic Insulin Signaling* , 2005, Journal of Biological Chemistry.

[39]  A. Cederbaum,et al.  A high‐fat diet leads to the progression of non‐alcoholic fatty liver disease in obese rats , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  R. Green,et al.  Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[41]  J. George,et al.  Fatty liver disease: NASH and related disorders , 2004 .

[42]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. , 2004, Human pathology.

[43]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[44]  T. Mak,et al.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. , 2004, The Journal of clinical investigation.

[45]  I. Leclercq,et al.  Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice , 2004, Hepatology.

[46]  K. Mak,et al.  Model of nonalcoholic steatohepatitis. , 2004, The American journal of clinical nutrition.

[47]  D. Purdie,et al.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life , 2004, Gut.

[48]  J. Kench,et al.  Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression , 2003 .

[49]  J. Altomonte,et al.  Fat depot-specific expression of adiponectin is impaired in Zucker fatty rats. , 2003, Metabolism: clinical and experimental.

[50]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[51]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[52]  A. Koteish,et al.  Animal models of steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.

[53]  Shelly C. Lu,et al.  Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  I. Leclercq,et al.  Leptin is essential for the hepatic fibrogenic response to chronic liver injury. , 2002, Journal of hepatology.

[55]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[56]  Mehrdad Nadji,et al.  Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E‐related disorders in humans , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  Y. Takei,et al.  Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals , 2001, Hepatology.

[58]  Shelly C. Lu,et al.  Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[60]  I. Leclercq,et al.  CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. , 2000, The Journal of clinical investigation.

[61]  C. Tsigos,et al.  Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. , 1999, Metabolism: clinical and experimental.

[62]  J. Parks,et al.  Mitochondrial abnormalities in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.

[63]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[64]  A. Burt,et al.  Diagnosis and interpretation of steatosis and steatohepatitis. , 1998, Seminars in diagnostic pathology.

[65]  R. Hammer,et al.  Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. , 1998, Genes & development.

[66]  C. Fan,et al.  Steatohepatitis, Spontaneous Peroxisome Proliferation and Liver Tumors in Mice Lacking Peroxisomal Fatty Acyl-CoA Oxidase , 1998, The Journal of Biological Chemistry.

[67]  J. Goldblum,et al.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[68]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[69]  M. Clemens,et al.  Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[70]  G. Bray,et al.  Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. , 1979, Physiological reviews.

[71]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[72]  M. Goettsch Comparative Protein Requirement of the Rat and Mouse for Growth, Reproduction and Lactation Using Casein Diets , 1960 .

[73]  Leah Hennings,et al.  A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[74]  I. Leclercq,et al.  Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARγ agonist pioglitazone , 2007, Laboratory Investigation.

[75]  C. Day From fat to inflammation. , 2006, Gastroenterology.

[76]  G. Farrell,et al.  LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis , 2006 .

[77]  J. Joven,et al.  Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis , 2005, Molecular and Cellular Biochemistry.

[78]  R. Green,et al.  The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. , 2004, Journal of hepatology.

[79]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.